- Chennai Today
- RELIGION. Mahabharatham: Rama Dikshithar, Sri Krishna Gana Sabha, 6.30 p.
- Merck Goes To Court Against Gilead Sciences
- In a note, Bloomberg intelligence analyst Asthika Goonewarden, recently wrote: “Gilead can easily handle the charge. Sure, investors won't be thrilled, but that's assuming Gilead rolls over and plays and dead and gives Merck 10 percent -- that's highly ...
- Can Biogen Inc (BIIB) Stay Relevant for Investors?
- So, not one of those really small biotech companies that will only deliver something very promising five to seven years down the line,” said Asthika Goonewardene, a BI analyst. Last December, there were also speculations that Baxalta Inc.
- Gilead Spars With Merck Over Hepatitis C $1000-Pill Royalties
- Even if it loses, Bloomberg Intelligence analyst Asthika Goonewardene said, the company should be able to weather a penalty of that size.
- Compelling Reasons For A Biogen And Shire Merger
- Investors believe that Biogen should expand through strategic acquisition for immediate revenue growth and to beef up its drug portfolio.
Asthika is described in multiple online sources, as addition to our editors' articles, see section below for printable documents, Asthika books and related discussion.
Suggested News Resources
Great care has been taken to prepare the information on this page. Elements of the content come from factual and lexical knowledge databases, realmagick.com library and third-party sources. We appreciate your suggestions and comments on further improvements of the site.